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A STUDY OF MORPHOLOGICAL, IMMUNOHISTOCHEMICAL AND 
HISTOCHEMICAL FEATURES. OF AMPULLARY CARCINOMAS. 
Carcinoma of the ampulla of Vater has been recognized as a clinically distinct entity. 
These are rare tumours and the treatment of choice is the Whipple procedure 
(pancreaticoduodenectomy). This is a formidable operation which is associated with 
morbidity and mortality. If reliable prognostic factors (clinical and histopathological) can 
be identified, then the choice of surgery - Whipple procedure or a palliative procedure­
would be made easier, and such identification may even be valuable in choosing 
patients with poor prognostic features for adjuvant treatment. This was a predominantly 
retrospective study of 37 unequivocal ampullary carcinomas after Whipple resection. 
The aim of the first study was to examine clinical, histopathological and 
immunohistochemical features of ampullary carcinomas and to determine whether any of 
these features had significant prognostiC value. The immunohistochemical panel was 
selected after a literature review and included p53, Ki-67, MUC1, MUC1core, MUC2 and 
CA 19.9. The data was analyzed by multivariate analysis. The relatively small number of 
patients included in this study was the result of the rarity of the tumour and strict 
selection criteria for ampullary carcinomas. In addition, 10 patients were lost to clinical 
follow up. Nevertheless, the results confirmed the good prognosis of T1 and stage 1 
carcinomas and suggested a possible role for MUC1 and MUC2 in the diagnosis of 
ampullary carcinoma in small endoscopic biopsies. None of the immunohistochemical 
stains could identify a subset of tumours with better or worse outcome. Vascular 
invasion, lymphatic invasion, perineural invasion, differentiation, Martin's classification, 
resection margins and histological sub-typing also did not appear to influence survival in 
this study. The aim of the second study was to ascertain whether the histochemical 
mucin profile of ampullary carcinomas correlated with the histological subclassification. 
The nature of the mucin produced by the carcinoma was demonstrated with the High 
iron diamine and the ABPAS stains. There was no pattern of mucin production which 
correlated with the histological subclassification and the validity of subclassifying 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
Ampullary tumours are relatively rare and represent 2% of all digestive tract tumours 
(1). Carcinoma of the ampulla of Vater has been recognized as a clinically distinct entity. 
However, the similarity in presentation to that of carcinoma of the pancreas, of the distal 
common bile duct, and the adjacent duodenal mucosa has in many cases resulted in 
failure to distinguish the clinical and pathological behavior of these tumours (2). 
The treatment of choice for ampullary carcinoma is the Whipple procedure 
(pancreaticoduodenectomy) (3). This is a formidable operation which is associated with 
morbidity and mortality. If reliable prognostic factors (clinical and histopathological) 
can be identified, then the choice of surgery - Whipple procedure or a palliative 
procedure - would be made easier, and such identification may even be valuable in 
choosing patients with tumours with poor prognosis for adjuvant treatment (4). 
1.1 ANATOMY OF THE PERIAMPULLARY REGION 
The ampulla was described by the German anatomist Abraham Vater in 1720. The 
ampulla is strictly defined as a dilated, jug-like conduit resulting from the union of the 
common bile duct and major pancreatic duct, and lies within the wall of the duodenum 
(5). It is now commonly accepted that the Vaterian system is composed of the distal 
segments of the common bile duct and major pancreatic duct (duct of Wirsung) at the 
duodenum, the papilla, and the sphincteric musculature. It also includes the extra 
duodenal portion of the 'common bile duct and major pancreatic duct that join to form a 
common channel outside the duodenal wall (6). It is a complex structural unit composed 
of highly developed mucosa, musculature and nerve supply that regulates the flow of 
bile and pancreatic secretions. Its sphincteric function is part of the overall 
gastrointestinal motility system (7). 
The papilla (Latin for nipple) is a cylindrical protuberance housing the terminations of 
the common bile duct and major pancreatic duct or a common channel, and is situated 












pylorus is a major landmark for finding the papilla, although the distance is variable, 
ranging from 1.5 to 12 cm, especially in the case of inflammation (9). 
The relationship of the common bile duct and the duct of Wirsung at the papilla is 
complex and has been the subject of several studies. The ducts may have separate 
openings into the duodenum, an interposed septum, or a common channel (Fig 1.1). In 
most studies, more than two thirds of these patients had a common channel. However, 
the frequency for separate openings into the duodenal lumen ranged from 12% to 54% 
and for a common channel, 36% to 88% (6,10-16). 
A B c 
D E 
Fig 1.1. Relationship of the common bile duct and the duct of Wirsung at the papilla: A) ampulla, 
B) interposed septum, C) separate openings, D) short common channel, E) long common channel 
and F) extended common channel [adapted from Histology for Pathologists (17)]. 
The sphincter of Oddi consists of the intrinsic circular and longitudinal musculature of 
the Vaterian system, which is embryologically and functionally distinct from the muscle 












the duodenum when necessary, and likely precludes the entry of duodenal contents into 
the bile duct or major pancreatic duct (7). 
Histologically, the ampulla represents a confluence of the epithelium from three 
different structures, namely the bile duct, the pancreatic duct and the duodenum. The 
epithelial lining of the pancreatic duct and the common bile duct are identical. The 
single layer of columnar lining cells has eosinophilic cytoplasm with basally located 
nuclei. Interspersed goblet cells increase closer to the ostium. The epithelium may 
undergo hyperplastic or metaplastic changes including mucinous cell hyperplasia, 
papillary hyperplasia, adenomatous hyperplasia, squamous metaplasia and pyloric 
gland metaplasia (18). The epithelium of the terminal portion of the common bile duct 
and common channel, if present, covers long slender papillary fronds or valvules, which 
in some respects resemble the fimbria of the fallopian tube. These formations are 
considerably larger than the duodenal villi, which are few or absent at the surface of the 
papilla (19). 
Dawson and Connolly (5) highlighted the differences in mucin secretion by the normal 
epithelia that convene at this point. The main pancreatic duct contains predominantly 
sulphated acid mucins. The duodenal surface mucosa contains sialomutins and 
Brunner's glands neutral mucins. The common bile duct contains predominantly 
sialomucins and a trace of sulphated mucins. The staining of the ampulla of Vater varies. 
Sialomucins predominate in the lining epithelium near the opening into the duodenum. 
Deeper in the ampulla the lining epithelium, as well as the glands lying beneath the 
epithelium, secrete principally sulphated mucins (5). 
1.2 PERIAMPULLARY CARCINOMAS 
The term "periampullary carcinoma" refers to carcinomas which arise from the mucosa 
of the ampulla of Vater, the distal pancreatic duct, the distal common bile duct, or the 












origin of periampullary carcinomas can not be overemphasized because carcinomas 
originating from the different periampullary sites, exhibit different clinical behaviors (4). 
The term "ampu1lary carcinoma" should only be employed for malignant epithelial 
tumours centered in the ampulla of Vater (20). Because of its location with respect to the 
biliary system, carcinoma of the ampulla of Vater is considered to present earlier in its 
course of development than carcinoma of the pancreas. The clinical course for patients 
with ampullary carcinoma has been recognized to be more favorable than that of 
patients with pancreatic carcinoma (4). 
Ampullary carcinomas account for 10.2% to 36% of all surgically operable 
pancreaticoduodenal tumours (21). Worldwide, the resectability rate for ductal 
adenocarcinoma of the pancreas ranges between 5% and 15%, morbidity and mortality 
rates are relatively high and the 5-year survival rate is 4% to 7% (22). Researchers from 
the Johns Hopkins hospital reported a 36% 5-year survival rate for 19 patients with 
ampullary carcinoma who had undergone pancreaticoduodenectomy, whereas for 50 
patients with pancreatic carcinoma who had undergone a similar procedure, the 5-year 
survival rate was 18% (23). In carcinomas from the biliary tract, location seems to be the 
most important prognostic factor. Lesions of the lower third are the most resectable and 
therefore associated with better results (24). In a study of distal biliary tumours at the 
Lahey clinic, the resectability was 100%, the median survival time was 16 months and 
the 5-year survival rate was 20% (25). Primary duodenal carcinoma accounts for 0.3% of 
all gastrointestinal malignancies. Its rarity has made the understanding of the biology of 
this tumour difficult. The 10 year survival rate of 20 patients treated at Kansas medical 
center between 1975 and 1990 was 67% (26). 
There is a clear trend for duodenal cancers to have the best survival and for pancreatic 
cancer to have the worst survival. Survival of patients with ampullary carcinoma 
generally follows closely behind those with duodenal carcinomas, whereas survival of 












tumours. Howe et al. found that in their cohort of periampullary carcinomas, the highest 
rates of resection and overall survival were in ampullary carcinomas (27). 
Whipple's observation that patients with ampullary carcinoma have improved survival 
relative to those with pancreatic cancer because of earlier presentation is borne out by 
the higher resectability rate of ampullary carcinomas. Allen Whipple stated: "Cancer of 
the pancreas is usually of the infiltrating, invasive, poorly differentiated type o/growth; the 
cancer cells invade the lymphatic and blood vessels and nerves early. Furthermore, the pancreatic 
tumours do not cause an early jaundice, as do carcinomas of the ampulla or the bile duct. The 
ampullary growths are usually of the fungating variety, the better differentiated of the 
adenomatous type, slower to invade the lymphatics and the blood vessels." (28). 
Howe et al. hypothesized that periampullary tumours represent a biologic spectrum of 
malignancies, where intestinal type tumours comprise the biologically more favourable 
end of the spectrum, and the pancreaticobiliary tumours the other (27). 
Neither clinical presentation nor the intraoperative macroscopic appearance allows for a 
clear distinction between ampullary and other periampullary carcinomas. These 
tumours often present to the surgeon in the same way and are treated along the same 
surgical principles. The differentiation between them is based almost entirely on 
macroscopic and microscopic examination of the resected specimen (29). 
1.3 EPIDEMIOLOGY AND DISEASE ASSOCIATIONS 
Most individuals are over the age of 60. In a large cohort of patients studied by 
Klemptnauer et aL, the median age was 62.2 years and the age range was 34 - 78 years 
(30). There is a slight male predominance and its incidence is increasing in men. A 20 
year population based study revealed age-standardized incidence rates of 3.8 per 
1000000 inhabitants in men and 2.7 per 1000000 inhabitants in women (31). 
Several significant disease associations have been described in association with 












adenomatous polyposis coli (AAPC), Gardner syndrome, neurofibromatosis type 1 (NF­
l) and pancreatic intra-epithelial neoplasia (panIN). 
• 	 FAP is an autosomal dominant familial syndrome which is characterized by 
numerous adenomatous polyps in the colon (a minimum of 100 polyps is 
required for the diagnosis) and a frequency of progression to colonic 
adenocarcinoma approaching 100% (32). Multiple adenomas may also be present 
elsewhere in the alimentary tract, including the ampulla of Vater. Offerhaus et aL 
found an increased relative risk for ampullary carcinoma in patients with FAP 
(33). Bjork et aL concluded that the lifetime risk of severe periampullary lesions 
in FAP patients is high, and an association between stage N periampullary 
adenomas and a malignant course of the periampullary adenomatosis is strongly 
suggestive (34). 
• 	 AAPC (previously known as flat adenoma syndrome) which genetically 
represents an extremely rare variant of FAP, is characterized clinically by many, 
but usually fewer than 100, colonic adenomas that are typically slightly elevated 
and plaque-like, with a reddish surface and sometimes a central depression. 
Several cases of concurrent AAPC and ampullary carcinoma have been reported, 
suggesting that AAPC should be considered in patients with ampullary tumours 
(35). 
• 	 Gardner syndrome is a variation of F AP, also autosomal dominant. Patients 
exhibit intestinal polyps identical to those in FAP, combined with multiple 
osteomas, epidermal cysts and fibromatosis (36). Almost all patients develop 
adenomas in the ampulla of Vater and are therefore at increased risk for 
developing ampullary carcinomas (37). 
• 	 NF-l (formerly known as von Recklinghausen's disease) is an autosomal 
dominant syndrome characterized by neurofibromas, pigmented skin lesions, iris 












Periampullary tumours in patients with NF-l are usually carcinoids or stromal 
tumours and, rarely, adenocarcinomas. Costi et al. reported that the ampullary 
and periampuliary adenocarcinomas in NF-l patients have peculiar features; the 
tumour may be part of a complex epithelial proliferation with associated islet cell 
adenomatosis of the pancreas and multiple gastric, duodenal and jejunal stromal 
tumours. Moreover, they occur at a younger age than those occurring in non-NF­
l patients (39). There is a strong association between somatostatin-producing 
carcinoids of the duodenum and NF-l (40). All the duodenal somatostatinomas 
are 	located either at the papilla of Vater or on the medial wall of the second 
portion of the duodenum. Patients with these tumours seldom exhibit the 
somatostatin syndrome (steatorrhoea, gall stones, diabetes mellitus and 
hypochlorhydria). Histologically, these tumours are usually typified by 
glandular/acinar structures lined by uniform cells with eosinophilic, granular 
cytoplasm. Solid or nested foci can also be present, and psammoma bodies are 
found in 60.7% of cases (41). Chetty and Essa (1999) propose that the 
somatostatin producing cells arise from pancreatic duct epithelium or from 
heterotopic pancreatic tissue; they postulate that these cells eventually evolve 
into somatostatinomas (42). 
• 	 Pancreatic intraductal neoplasia (panIN) is a precursor lesion for the 
development of pancreatic adenocarcinoma (40). Adenomas and carcinomas of 
the ampulla of Vater have a strong association with PanIN, and often high grade 
PaIN. Agoff et al. emphasized that PaIN is underreported and often 
unrecognized in specimens resected for ampullary carcinoma (43). 
• 	 Associations with unusual dermatological conditions have been reported which 
include the Leser-Trelat sign and Muir-Torre syndrome (MTS). The Leser-Trelat 
sign is the rapid and widespread eruption of multiple seborrhoeic keratoses. 
Klimopoulos et al. described a case of Leser-Trelat sign occurring in association 
with ampullary carcinoma (44). Matthews et al. described a case of an individual 












tumours and kerato-acanthomas with internal malignancies, who developed 
ampullary carcinoma (45). 
• 	 There is a greater frequency of other malignancies in survivors of ampullary 
tumours. This is 4 - 5 times greater than expected and not confined to 
gastrointestinal tract malignancies. Eriguchi et a1. reported 5 cases of ampullary 
carcinomas associated with malignancies in other organs, including gastric, 
colonic and pulmonary carcinomas (46). 
1.4 	ETIOLOGY AND PATHOGENISIS 
No definite aetiological factors such as diet, chemical or environmental causes have been 
directly linked to the pathogenesis of ampullary carcinomas. Much attention has been 
given to adenomas as precursor lesions for these tumours. 
Adenomas occurring in the ampullary region, including those arising in the papilla, 
have been termed ampullary adenomas (47). The duodenum is the least common site for 
an adenoma and most duodenal adenomas occur in the vicinity of the ampulla of Vater 
(48). It has been postulated that carcinogens, or co-carcinogens present in bile or 
pancreatic secretions may playa role in the etiology of adenomas, because most of them 
occur near the ampulla (49). An established risk factor is the presence of genetically 
inheritable polyposis syndromes e.g. F AP (34). Evidence which strongly suggests that 
ampullary adenomas are precursor lesions for ampullary carcinomas is: (47) 
• 	 Adenomatous foci are found in adenocarcinomas 
• 	 Histological appearance identical to the appearance of adenomas of the large 
bowel 
• 	 Increasing grade of dysplasia during follow up 
• 	 Genetic changes are comparable to IIpremalignant" lesions of other 
gastrointestinal sites 













It is therefore reasonable to postulate that the adenoma-carcinoma sequence is as 
significant in the ampullary region as in the co10recta1 area. 
1.5 MOLECULAR PATHOLOGY 
• 	 p53: It has been well established that disturbances in the cell cycle, with an 
increase in proliferative activity, occurs during carcinogenesis. For ampullary 
adenomas, an enhanced cellular proliferation has been reported as compared to 
non-neoplastic mucosa. Mutations of p53 have been found in ampullary 
adenocarcinomas but not in adenomas or inflamed precursor lesions (50). In a 
study by Takashima et a1., positivity of p53 was 0% in pure adenomas, 36% in 
adenomatous areas of carcinomas with adenomatous areas, 62% in the 
carcinomatous areas of carcinomas with adenomatous areas, and 56% in pure 
carcinomas. They concluded that molecular events leading to p53 accumulation 
occur relatively late during the oncogenic process (51). 
• 	 K-ras: K-ras codon 12 point mutations occur in about 40% of ampullary 
neoplasms at a relatively early stage in tumourogenesis. The pattern of mutations 
in these tumours resembles that of the adenoma-carcinoma sequence in the colon 
and rectum. It has been suggested that ampullary neoplasms can be detected at 
an early stage by searching for genetic alterations in the K-ras oncogene in 
cytological brush specimens (52). 
• 	 Dpc4: The Dpc4/Smad4 gene encodes a component of the transforming growth 
factor (TGF) beta signaling pathway. It functions as part of various DNA binding 
transcriptional activator complexes (53). Loss of Dpc4 expression occurs in 
approximately one third of invasive ampullary cancers but is not seen in 
adenomas; thus, loss of Dpc4 expression occurs late in ampullary carcinogenesis. 
Although ampullary and pancreatic adenocarcinomas share histological and 
molecular features, ampullary carcinomas are less likely to show loss of Dpc4 












clinical relevance, its involvement in ampullary cancers gives additional weight 
to the hypothesis that, among all pancreatic exocrine and endocrine tumours, 
only ampullary carcinomas and common ductal adenocarcinomas have similar 
molecular fingerprints (53). 
• 	 Microsatellite instability (MSI): Park et aI. investigated the occurrence of 
microsatellite instability in 64 ampullary neoplasms. Eight out of 22 adenomas, 
nine out of 32 carcinomas and one metastatic lesion showed MSI in 1 - 3 of the 
nine dinucleotide markers; those cases are categorized into microsatellite 
instability-low. The remaining samples were stable. None of the samples showed 
frame shift mutations of the poly A-tract of the factor-beta type II receptor which 
are frequently mutated in gastric or colorectal cancers showing MSI. To confirm 
this finding, the neoplasms were stained with hMLHl and hMSH2 and all 
tumours were found to express mismatch repair proteins. They concluded that, 
in contrast to gastric and colorectal cancers, MSI does not play an important role 
in the carcinogenesis of ampullary carcinoma. (55) 
• 	 Mucin carbohydrates and core proteins: Kitamura et al. examined the 
expression of carbohydrate antigens which are associated with the earliest steps 
in mucin glycosylation (Tn and sialosyl-TN) and the expression of mucin core 
antigens associated with MUCI gene product (DF3 antigen) as well as MUC2 
gene product in 36 ampullary carcinomas. MUCl, Tn and sialosyl TN showed a 
high expression rate in carcinoma and rare or no expression in non-neoplastic 
epithelium around carcinoma. The expression of MUCI and MUC2 was also a 
useful indicator of the prognosis of the patients (56) (see Survival and Prognosis). 
• 	 Other: Loss of heterozygosity of chromosome 5q occurring in the early stages of 
ampullary carcinoma have been demonstrated (57). Mutations of the APC gene 












1.6 CLINICAL PRESENTATION 
Commonly, the physical findings are due to biliary obstruction early in the disease 
process. Jaundice, abdominal pain and significant weight loss (more than 10% of body 
weight) are the most frequently reported symptoms. Biliary colic, pancreatitis and 
haemorrhage have also been reported. The duration of symptoms ranges from 2 - 4 
months (1, 58, 59). Duffy et al. described eight patients out of 55 consecutive resections 
who were completely asymptomatic and their periampullary lesions were discovered on 
work ups which had been initiated by abnormalities on routine serum liver function 
tests; three of these patients developed jaundice during the course of the workup. 
Hepatomegaly and anaemia are common clinical findings and palpable gall bladder is 
found in 30% of cases. Occult blood may be detected in stool samples (58). 
Abnormalities in biochemical results are variable. An increase in serum alkaline 
phosphatase and low grade elevation of serum bilirubin are common findings. Other 
abnormal laboratory examinations include elevated alanine transaminase, aspartate 
transaminase and decreased haemoglobin levels in those patients with haemorrhage and 
malena (60). 
1.7 DIAGNOSTIC PROCEDURES 
1.7.1 RADIOLOGY 
Before 1987 different diagnostic procedures were performed on indication. After 1987, 
diagnostic imaging was gradually standardized to include conventional 
ultrasonogrophy, computed tomographic (Cf) scanning, endoscopic retrograde 
cholangiopancreaticography (ERCP), endoscopic ultrasonography, and selective 
angiography (61). 
Duodenoscopy with ERCP indisputably seems to be the best investigation for the 












biopsied during ERCP, but biliary drainage by papillotomy and/or the insertion of an 
endoprosthesis may be attempted (62). 
Sonography or CT scanning can be performed rapidly and easily on the jaundiced 
patient and each is capable of demonstrating the distal location of the obstruction and 
the dilatation of the common bile duct. However, visualization of the ampullary tumour 
is more difficult and operator dependant. In a series by Chareton et al., an ampullary 
tumour was suggested in only 13% of patients undergoing sonography and 23% of 
patients undergoing CT scanning. CT scan is recommended where staging is necessary 
or as ancillary work up to augment the findings of the previous examinations (1). 
Echoendoscopy seems to hold promise for the evaluation of lymph node involvement or 
mesenteric portal vein encasement (63, 64). Pre-operative angiography may be used to 
evaluate the resectability of tumours with regard to the vessels of the portal system (65). 
1.7.2 FINE NEEDLE ASPIRATE AND BIOPSY 
The diagnosis of ampullary carcinoma can be made by endoscopic biopsy, 
transduodenal biopsy or cytological examination. 
1.7.2.1 CYTOLOGICAL EVALUATION 
Endoscopic brush cytology is an effective means of diagnosing ampullary neoplasms, 
and it complements tissue biopsy in cases of bile duct stricture. Location, predominance 
of tumour stroma, an extramucosal growth pattern, sampling error, and interpretative 
experience influence the diagnostic evaluation. Cytological diagnosis of an adenoma 
does not exclude an underlying malignant neoplasm in ampullary tumours. In some 
instances, it may be difficult to distinguish between villous tumours with severe 












1.7.2.2 HISTOLOGICAL EVALUATION 
Endoscopy and biopsy assume a major role in obtaining an accurate preoperative 
diagnosis. Pure adenomas can be locally excised, whereas adenomas that harbor 
invasive carcinomas require more extensive surgical procedures (67, 68). It is important 
to remember that in up to 50% of cases, the biopsy of a villous adenoma could miss the 
malignant tumour (69, 70). The biopsy should not be too superficial, or else areas of 
malignant change can be missed. The biopsy specimen should preferably should be in 
the form of multiple samples which are step sectioned, a procedure which is claimed to 
have a diagnostic reliability of greater than 90% (71). From a diagnostic point of view, 
other benign lesions also need to be excluded, which include Brunner gland hamartomas 
and Peutz Jeghers polyps (60). Frozen section evaluation has been reported to be 
inaccurate in detecting foci of adenocarcinoma of the ampulla of Vater, leading many 
authors to advocate pancreaticoduodenectomy as the method of treatment for these 
neoplasms. However, Gary et al. claim that frozen section evaluation of ampullary 
neoplasms is accurate. These authors advocate that ampullary resection is less morbid 
than pancreaticoduodenectomy and ampullary resection with frozen section is their 
current approach to small ampullary lesions (67). 
1.8 PATHOLOGY 
1.8.1 MACROSCOPIC 
Grossly, ampullary carcinomas usually bulge into the duodenal lumen. The duodenal 
mucosa appears stretched but otherwise normal if the tumour is confined to the 
ampullary lumen. In other instances, the tumour presents mainly as a circumferential 
growth around the ampulla. In still others, a combined pattern of growth exists (72). 
Lechago et al. classifies ampullary tumours as 'intra-ampullary, periampullary and 
mixed types' according to location (73). (The term periampullary tumour in this 
classification based on location, should not be confused with the earlier definition where 













In a study by Howe et al. the mean size of resected ampullary carcinomas was 2.7 em 
with a median size of 2.5 cm and a range of 0.3 - 10.3 cm (27). Those tumours with a 
prominent component of residual villous adenoma present as soft, sessile, papillary 
masses projecting into the duodenal lumen. The tumours may be exophytic and/or 
ulcerating (21). 
1.8.2 MICROSCOPIC 
The majority of the malignant ampullary tumours are adenocarcinomas. Many of them 
have a superficial papillary component with the appearance of villous adenoma or 
villoglandular polyp (74). The WHO classification of tumours groups ampullary 
carcinomas under the carcinomas of the extra-hepatic biliary tree. The intestinal type is 
defined as an unusual variant of adenocarcinoma (75). A modified classification of 
carcinomas of the extrahepatic bile ducts, published in 2000 by the World Health 
Organization (WHO), which is applicable to ampullary carcinomas, is as follows :( 75, 
76) 
• Carcinoma in situ 
• Papillary adenocarcinoma 
• Adenocarcinoma, intestinal type 
• Mucinous adenocarcinoma 
• Clear cell carcinoma 
• Signet ring cell carcinoma 
• Adenosquamous carcinoma 
• Squamous cell carcinoma 
• Small cell carcinoma 
• Undifferentiated carcinoma 
• Carcinoid tumour 
• Mixed carcinoid-adenocarcinoma 
• Carcinoma, NOS 












Albores-Saavedra et al. (77) classifies ampullary carcinomas into the main types and the 
so called"unusual types". 
The "main types" are the pancreaticobiliary and the intestinal types, which 
reflect the origin from two different types of mucosa at this site. The 
morphological criteria are as follows: The intestinal type carcinoma is composed 
of well formed tubular to elongate glands, complex cribiform areas and solid 
nests, indistinguishable from colorectal adenocarcinoma. The pancreaticobiliary 
type carcinomas mostly consist of simple or branching glands and small solid 
nests of cells surrounded by desmoplastic stroma. 
The "unusual types" include signet ring cell carcinoma, mucinous, squamous cell 
carcinoma, adenosquamous carcinoma and undifferentiated carcinoma. Other 
unusual variants described include cases with a prominent Panneth cell 
component, cases exhibiting hepatoid differentiation and small cell 
(neuroendocrine) carcinomas. 
Studies have shown that the majority of ampullary carcinomas (44% - 72%) are of the 
pancreaticobiliary type, the second most common group of carcinoma (25% - 27%) are of 
the intestinal type, whilst the rest are mixed and unusual types (78, 79). 
A recent study attempted to objectify the classification of ampullary carcinomas by 
immunohistochemical criteria. They found a distinctly different cytokeratin expression 
in the pancreaticobiliary types and in the intestinal types, using the cytokeratin 20 
(CK20) and cytokeratin 7 (CK7) profile. Ampullary carcinomas expressing CK20 but not 
CK7 reflect the normal cytokeratin spectrum of intestinal mucosa, whereas carcinomas 
reacting positive for CK7 but negative for CK20 reflect the profile of pancreaticobiliary 
duct mucosa. The histological classification and the immunohistochemical 
characterization by cytokeratins were in good agreement (79). MUC2 apomucin 












ampu1lary carcinomas. Most intestinal type carcinomas were MUC2 positive while none 
of the panreaticobiliary type carcinomas expressed this mucin (78). 
The prognostic significance of these classifications is doubtful. Kimura et al. found a 
significantly better prognosis for patients with intestinal type ampullary carcinomas 
than with pancreaticobiliary type carcinomas (80). In the collective of Memorial Sloan 
Kettering Cancer Center, the outcome of the intestinal type tumours was somewhat 
more favorable than that of the pancreaticobiliary type. However, in the collective of 
Zhou et aI., neither the histopathological classification nor the immunohistochemical 
classification identified a subgroup of tumours with a better or worse outcome (79). 
1.9 GRADING AND STAGING 
1.9.1 HISTOLOGICAL GRADE· 
For non-papillary adenocarcinomas, the following grading system is suggested (76): 
• GX Grade can not be assessed 
• G1 Well differentiated (>95% of the tumour composed of glands) 
• G2 Moderately differentiated (50-95 % of the tumour composed of glands) 
• G3 Poorly differentiated (5-49% of the tumour composed of glands) 
• G4 Undifferentiated «5% of the tumour composed of glands) 
1.9.2 STAGING 
The TNM staging system for ampullary tumours of the American Joint Committee on 
Cancer (AJCC) and the International Union against Cancer (UICC) is recommended (81): 
Primary tumour (T) 
• TX Primary tumour cannot be assessed 
• TO No evidence of primary tumour 












• 	 T1 Tumour limited to the ampulla of Vater or the sphincter of Oddi 
• 	 T2 Tumour invades the duodenal wall 
• 	 T3 Tumour invades 2cm or less into the pancreas 
• 	 T4 Tumour invades more than 2cm into the pancreas and/or into the adjacent 
organs 
Regional lymph nodes (N) 
• 	 NX Regional nodes can not be assessed 
• 	 NO No regional lymph node metastasis 
• 	 N1 Regional lymph node metastasis 
Distant metastasis (M) 
• 	 MX The presence of distant metastasis can not be assessed 
• 	 MO No distant metastasis 
• 	 M1 Distant metastasis 
Stage groupings 
Stage 0 Tis NO MO 
Stage I T1 NO MO 
Stage II T2 NO MO 
T3 	NO MO 
Stage III 	 T1 N1 MO 
T2 N1 MO 
T3 N1 MO 
Stage IV 	 T4 AnyN MO 
AnyT AnyN M1 
Although tumour size was not included in the TNM staging system for ampullary 












Tumour size 5-year survival rate (% + SE) 
<2.5cm 65% 
>2.5cm 20% 
Martin's classification is as follows (59): 
• 	 Stage I: vegetating tumour limited to the epithelium with no involvement of the 
sphincter of Oddi. 
• 	 Stage II: tumour localized in the duodenal submucosa without involvement of 
the duodenal muscularis propria but possible involvement of the sphincter of 
Oddi. 
• 	 Stage III: tumour of the duodenal muscularis propria. 
• 	 Stage IV: tumour of the periduodenal area or the pancreas, with proximal or 
distal lymph node involvement. 
1.10 TREATMENT 
Pancreaticoduodenectomy, specifically pylorus preserving pancreaticoduodenectomy, 
seems to be current choice of operation, even for benign ampullary tumours. Proper 
patient selection and careful technique continue to be the most important factors in 
minimizing morbidity and peri-operative mortality (83). 
1.10.1 PANCREATICODUODENECTOMY (PD) 
PD has its origin in the late 1800s. Halsted performed the first transduodenal local 
excision of an ampullary tumour in 1898 (84). Allesandro Codivilla, in that same year, 
was the first to perform a PD in Imola, Italy. Allen Oldfather Whipple (1881-1963) was 
an American surgeon who reported the first series of PDs in 1935, and since that time 
the operation has been known as the "Whipple operation"(85). PD generally involves 
the removal of the gall bladder, common bile duct, variable lengths of the duodenum 
and/or stomach and the head of the pancreas. There are several variations of this 












with ampullary tumours are the classici standard PD (includes antrectomy) and the 
pylorus preserving pancreatico duodenectomy (PPPD) (58). 
PD is performed VIa subcostal or midline incision. After thorough abdominal 
exploration the gall bladder is removed and the common bile duct is transected. The 
anterior aspect of the portal vein is then dissected free of the overlying pancreatic neck. 
Subsequently the duodenum (in the PPPD) or the stomach (in the classici standard 
procedure) is transected, followed by transaction of the pancreatic neck, unicate process 
and the jejunum distal to the ligament of Treitz. Truncal vagotomy is performed in most 
patients undergoing hemi-gastrectomy. Reconstruction is undertaken with an 
isoperistaltic limb of jejunum in retrocolic fashion and anastomosed with an end-to-side 
pancreaticojejunostomy followed by an end-to-side choledochojejunostomy and an end­
to-side duodenojejunostomy or gastrojejunostomy. An alternative for pancreatic-enteric 
reconstruction involves the use of a pancreaticogastrostomy (83). 












Fig 1.3. Most common anatomy after a Whipple resection [Adapted from Schmidt et al. (83)] 
PD is a complex operation that previously carried a very high post-operative mortality. 
Numerous studies have examined the outcomes of PDs for ampullary cancer. The 
problem is that many of these studies include cases operated on during multiple 
decades by many different surgeons with significant variation in surgical technique. 
Furthermore, some of the reports review operative outcomes of PDs at a time when the 
procedure carried with it a risk of substantially higher mortality than it does today (86, 
87). During the last two decades, improvements in surgical and anesthetic techniques, 
critical care and institutional specialization have decreased peri-operative mortality rates 
to below 5% in most major centers (23, 88). Brent et al. reviewed 279 patients who 
underwent PD from 1980 to 1989 at a single institution with a postoperative mortality of 
4% (89). In a recent article, Duffy et al. reviewed an approximately 13 year experience 
(from 1988 through 2001) with Whipple resection, both standard and pylorus preserving 
types, for adenocarcinoma of the ampulla of Vater: there were no operative deaths, and 
all patients left the hospital (58). 
Despite the decline in mortality associated with PD, postoperative morbidity continues 












the patients (46% - 49%) after PD (83, 89). The most common complications are 
pancreatic fistula, delayed gastric emptying, sepsis and anastomotic leaks. Risk factors 
generally associated with an increased rate of complications included prolonged 
operations, increased operative blood loss and advanced age (89). 
PPPD provides, in contrast to the standard Whipple procedure, preservation of the 
stomach, the pylorus and the first 2 cm of the duodenum. This is technically an easier 
operation than the standard Whipple procedure and preservation of the pylorus seems 
to improve post-operative digestive function and weight gain. There is also no reflux of 
bile into the stomach (90, 91). Preservation of the pylorus does not appear to alter 
mortality, post-operative morbidity or the hospital stay in any significant way. 
However, the duration of the operation is shorter and fewer blood units are transfused 
during the operation (I, 90, 91). In patients that underwent PPPD, gastric emptying may 
be prolonged during the post-operative period. Although delayed gastric emptying 
occurred more commonly in patients who underwent PPPD in a study by Duffy et aL, 
the difference was not statistically significant (58). 
Total PD does not seem to be indicated for ampullary tumours except when the tail of 
the pancreas must be or was previously resected for some reason (1). In a cohort by 
Allema et aL, subtotal PD was the type of resection in 62 patients and in 5 patients, total 
PD was performed. The indications for PD was tumour involving the pancreatic 
resection margin with intra-operative frozen section histological evaluation, and when 
the remnant pancreatic duct was too friable for a safe pancreaticojejunostomy. The 
hospital mortality. and morbidity after subtotal PD was significantly lower than the 
mortality and the morbidity for total PD (3). 
1.10.2 AMPULLECTOMY 
The first ampullary resection was performed by Halsted in 1897. The technique has been 
refined and standardized over the years (92). There has been much debate over the place 












resection is only applicable for stage 0 and I tumours, small neuroendocrine tumours 
and benign lesions < 3 em. However, it may be very difficult pre- and post-operatively, 
to determine whether the tumour is limited to the ampulla or whether it infiltrates 
adjacent structures. Mucosal spread or intestinal infiltration was frequently found even 
with cases with carcinoma at a relatively early stage (93). FincH tumour staging is only 
possible after definitive histopathological examination of the resected specimen (76). 
Studies have found that post-operative mortality is equivalent (93, 94), or even higher 
(96) than that after PD; long term survival is not modified (95, 97). Ampullectomy is 
often associated with post-operative haemorrhage (1). Moreover endoscopic surveillance 
is necessary every six months and occaSionally, a secondary PD is required (97). 
Chareton et al. reported a series of 63 ampullary tumours. Two of the patients had 
undergone simple ampullectomies for benign disease, both of which were classified as 
stage IV according to Martin's classification (one having undergone PD and the other 
simple exploratory laparotomy) 4 and 22 yei:irs after the local resections (1). Although 
this potentially curable malignancy should preferably be treated with adequate radical 
resection, some authors still advocate that local resection may be possible in the 
treatment of very small tumours (as long as the lesion is removed with intra-operative 
frozen section examination) and the treatment of high risk elderly patients (93). 
1.10.1 PANCREAS SPARING DUODENECTOMY (PSD) 
Chung et al. stated that PSD, as well as local resection, is not appropriate for duodenal 
(including ampullary) malignancies, early or late, because the recurrence rate is high. 
However, conservative procedures may have a role in the treatment of large villous 
adenomas (98). 
1.10.2 ADJUVANT THERAPY 
To limit the development of local recurrence, physicians have made use of adjuvant 
therapy for patients with ampullary carcinoma. Barton and Copeland reported 56 
patients with ampullary carcinomas, 17 of which received post operative chemotherapy 












stated that no combination of drugs appeared to prolong life when used in either the 
adjuvant or the therapeutic setting (99). Scmidt at al. reported a 20-year experience of 
295 patients who underwent PD for periampullary carcinoma. The study included 49 
ampullary carcinomas. Chemotherapy, radiotherapy or combined chemo-radiotherapy 
for periampullary adenocarcinomas in general, without any subgroup analysis, did not 
seem to confer a survival advantage with those with known follow up (83). However, in 
a retrospective review, Chan et al. reported that 13 patients who received adjuvant 
chemotherapy (predominantly involving 5-fluorouracil, mitomycin-C and doxorubicin) 
had a significantly better survival than 16 patients who underwent resection alone (4). 
Yeung et al. found no residual tumour in specimens for PD performed for four patients 
with duodenal/ampullary carcinomas who had received neoadjuvant chemotherapy 
(100). The combination of intra-operative radiation and resection has not added any 
significant benefit to patients with ampullary and bile duct cancer when compared with 
resection alone (101). 
Adjuvant therapy was not offered to most patients before 1990. As a result the data on 
patients treated with chemo-radiation is relatively small with conflicting results. 
Currently, adjuvant therapy is advocated mainly for patients with poor prognostic 
features (102). Theoretically, patient survival should be extended by adjuvant treatment. 
However, some studies have actually shown decreased survival rates in patients that 
received adjuvant therapy, compared to those who have not. The reason for this is 
probably that the patients who received adjuvant therapy are also the patients with the 
"unfavorable" tumour characteristics. This fact makes the interpretation of comparative 
studies difficult. More studies need to be undertaken before drawing any conclusion 
(58). 
1.10.3 LASER TREATMENT 
For unresectable tumours, several authors have proposed laser destruction after 












disappointing as mortality is close to 10%; and there have been no notable modifications 
in outcome, as the mean survival remains at approximately 6 months (103, 104). 
1.10.4 BYPASS OPERATIONS 
When the tumour is umesectable, bypass operations have been considered, even though 
their associated mortality and morbidity are high. Moreover, these operations leave a 
potentially haemorrhagic tumour in place. In a series reported by Divinagracia et aI, 
palliative management with bypass procedure alone was shown to have 100% post 
operative mortality (60). 
1.11 SURVIVAL 
Different criteria for classification of ampullary carcinomas make a comparison of 
different collectives difficult. Additional confusion is generated by the fact that 
ampullary carcinomas are often grouped together with other periampullary tumours. 
The identification of prognostic factors is important to predict the survival probability 
and to draw consequences for rational and pragmatic surgical therapy (29). 
The 5-year survival rates after resection is usually between 30% and 60% (1, 3-5, 19,58, 
87). Klempnauer et al. reported that survival probability increased with each year that a 
patient survived after resection. When a patient had already survived five years after 
resection, the probability to survive another 5 years was 83 % (29). Prognostic factors can 
be divided into patient, tumour and treatment associated factors. 
Tumour characteristics: 
• 	 Histogenesis: the importance of distinguishing ampullary carcinomas from other 
periampullary carcinomas has already been discussed. The resection rate and the 
prognosiS are significantly higher in comparison with pancreatic 












• 	 TNM and stage groupings: the post resection prognosis of a patient with 
ampullary carcinoma is primarily determined by the anatomic extent of the 
disease as defined by TNM classification and stage groupings (105-110). 
• 	 Lymph node involvement: lymph nodes metastases have been shown to have 
independent significance as an adverse prognostic factor (106,107,111). 
• 	 Tumour size: although not included in the TNM system, it has been shown to 
have independent prognostic significance [see Grading and Staging] (82). 
• 	 Histologic grade: poor differentiation has been shown to be an adverse 
prognostic factor (105, 106). 
• 	 Histologic type: ampullary tumours of the papillary type have been shown to 
have a favourable prognosis compared to non-papillary types (105). Signet ring 
cell carcinomas are, by convention, classified as poorly differentiated 
adenocarcinomas, and poor differentiation has been shown to be an adverse 
prognostic factor (105, 106). As mentioned earlier, Kimura et aL found a 
significantly better prognosis for patients with intestinal type ampullary 
carcinomas than with pancreaticobiliary type carcinomas (80). In a study by 
Beghelli et al. only T -stage and histolOgical type emerged as independent 
prognostic factors: the median actuarial survival time was 19 months for patients 
with pancreatobiliary cancers, whereas it was 70 months for patients with 
intestinal type cancers. (53) However, this could not be confirmed by Zhou et al. 
(79). 
• 	 Local extension: invasion of the muscle of the sphincter of Oddi has been shown 
to be an adverse prognostic factor (105). 
• 	 Blood/Lymphatic invasion: lymphatic and small blood vessel invasion have 
been shown to be an adverse prognostic factor (105, 109). 
• 	 Perineural invasion: perineural invasion by the tumour has been shown to be an 
adverse prognostic factor (105). In a study by Duffy et aI., the major factor 
associat~d with prolonged survival was the absence of perineural invasion in 
resected tumour specimens (58). 
• 	 Resection margins: involvement of resection margins have been shown to be an 












region of the pancreatic head, most often arises in corresponding to the deep 
radial posterior margin of the pancreatic head. Local recurrence from intraductal 
tumour is most likely to occur at a ductal resection margin (Le., the main 
pancreatic duct and/or the common bile duct margin) (106). Allema et al. 
concluded that involvement of resection margins was the strongest prognostic 
factor for survival and that patients with involved margins may be candidates . 
for adjuvant therapy (3). 
Special tests 
• 	 Intratumoural microvessel density (IMD): angiogenesis is required for tumour 
growth. Khan et al. examined the IMD in 24 pancreatic carcinomas and 23 
ampullary carcinomas with CD34. In the pancreatic cancer group IMD was 
found to have independent prognostic significance to survival on multivariate 
analysis. For ampullary cancers, IMD was higher in those with lymph node 
metastasis (P=O.02, Mann-Whitney U-test) (110). 
• 	 Expression of mucin carbohydrates and core proteins: Kitamura et al. found that 
the patients with positive DF3 antigen (MUC1 gene product) expression in the 
carcinoma showed Significantly poorer survival than those with negative DF3 
expression, whereas the patients with positive intestinal-MRP (MUC2 gene 
product) in the carcinoma showed significantly more favourable survival than 
those with negative intestinal-MRP expression (56). 
• 	 MIB-1/Ki-67 labeli g index: MIB-1 has been shown to have independent 
prognostic significance in ampullary carcinomas. The 5-year survival rate was 
40.7% for tumours with a MIB-1 index <or= 15%, and 0% for those with MIB-1 
index> 15% (113). 
• 	 Ploidy: diploid tumours have been shown to have a significantly better prognosis 
than aneuploid tumours (113). 
• 	 Cyclin D1 expression: Yamazaki et al. found increased Cyclin D1 expression by 
immunohistochemistry in 17 of 30 ampullary carcinomas. Cyclin D1 expression 
was significantly correlated with tumour cell proliferation and disease free 












• 	 CA19.9 expression: there are several reports on the poor prognosis of ampullary 
cancers expressing CA19.9 (115, 116). Dorendeu et al. confirmed this finding. 
However, the patient numbers were too small for multivariate analysis (59) 
• 	 Dpc4 expression: Dpc4 immunohistochemical staining is not significantly 
associated with any clinicopathological variable, including prognosis (53). 
• 	 p53 over-expression: Several studies concluded that accumulation of p53 protein 
revealed no significant difference in prognosis (51,59,79). 
Patient characteristics 
• 	 Age and sex: there is no significant correlation between age and survival (3). 
Zhou et al. found that the survival times of males were significantly shorter than 
females. lbis was probably due to the higher frequency of nodal positive 
carcinomas in males than in females (79). Yamaguchi et al. failed to reveal that 
the age of the patient at the time of operation was an independent prognostic 
factor (21). 
• 	 Pre-operative symptoms: there is no significant correlation between pre­
operative symptoms and survival (3). 
Treatment associated factors 
• 	 Adjuvant therapy: Chan et al. concluded that prognosis was better for ampullary 
tumours if adjuvant chemotherapy was used. Radiotherapy did not influence 
survival (4). 
• 	 Type of operation: although the type of operative procedure was a significant 
predictor of survival in one univariate analysis, prognosis depends more upon 












CHAPTER 2: MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES 
IN AMPULLARY CARCINOMAS 
This study entailed a histopathological and an immunohistochemical analysis of 
ampullary carcinomas in specimens following a Whipple resection. 
2.1 AIM 
• 	 To examine clinical, histopathological and immunohistochemical features of 
ampullary carcinomas after Whipple resection. 
• 	 To determine whether any of these features have significant prognostic value. 
2.2 MATERIALS AND METHODS 
A thesis proposal was submitted for approval to the Groote Schuur Hospital/University 
of Cape Town Human Ethics Committee and ethical approval was obtained. 
This was a retrospective study of 37 patients who underwent a Whipple resection for 
adenocarcinoma of the ampulla of Vater from 1979 through 2002. The resections were 
performed at Groote Schuur hospital which is an academic tertiary care hospital. Cases 
were only included in this study if one could confidently conclude from the macroscopic 
description on the original pathology report that the tumour truly arose from the 
ampulla of Vater. Tumours simply reported as "peri-ampullary" were excluded from 
this study. Patients who only had adenomas, ampullary fibrosis or other unusual 
tumours were excluded from this study. The expected number of cases was over fifty. 
Ultimately, only 37 cases could confidently be labelled as true ampullary carcinomas 
after review of the macroscopic description and histological evaluation. Formalin fixed, 
wax embedded tissue was retrieved from the archives of the Anatomical Pathology 
Division of Groote Schuur Hospital For each case a single block was chosen. The 
selected blocks contained the most representative sample of the carcinoma, and if 












had faded and these blocks were re-cut and re-stained with H&E. Microscopic tumour 
analysis confirmed that these tumours were all adenocarcinomas. 
2.2.1 HANDLING OF A RESECTED PANCREATICODUODENECTOMY SPECIMEN 
[Adapted from: Royal Collage of Pathologists' Minimum dataset for the 
histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma 
(118), College of American Pathologists' Protocol for the examination of specimens from 
patients with carcinoma of the ampulla of Vater (76) and Rosai and Ackerman's Surgical 
Pathology, 9th edition (119)]. 
• 	 The type of specimen is recorded, e.g. a standard Whipple 
pancreaticoduodenectomy (PD), a pylorus-preserving PD or a total PD. The 
standard PD includes the head of the pancreas, duodenum, distal bile duct, gall 
bladder and two thirds of the stomach; the pylorus preserving PD does not 
include the stomach; the total PD also includes the body and the tail of the 
pancreas with or without the spleen and/or stomach. 
• 	 Record the length, in millimeters, of the duodenum, stomach (lesser curve and 
greater curve), gall bladder, cystic duct and extra-hepatic bile duct, and the 
maximum dimensions of the pancreas. 
• 	 The circumferential margins of the pancreas (including the anterior, medial and 
retroperitoneal aspects) should each be painted with a different colour ink, either 
when the specimen is fresh or when fixed, according to the preference of the 
examining pathologist, but before the blocks are taken. 
• 	 To aid fixation, the duodenum and/or stomach should be opened. The common 
bile duct, the pancreatic duct and the termination onto the duodenum should be 
probed and opened (Fig 2.1). The relationship with each other should be 












portal vein) should be noted. The specimen may then be pinned to a cork board, 
placed in a large volume of formalin and allowed to fix for 24--48 hours. 
• 	 Record the site of the ampullary tumour as being intra-ampullary, peri ­
ampullary or from the junction of duodenum and ampullary mucosa. The extent 
of the tumour can be optimally visualized either by making transverse sections 
along the ampulla, or by serially slicing the entire specimen. 
Fig 2.1 . A). In this case the ampullary carcinoma almost completely replaces the major 
papilla. B) The dilated ampulla is opened to reveal an in-situ stent. C) The stent is removed and 












• 	 Optimally, three dimensions of the tumour should be measured but for staging 
purposes, at least the maximum diameter of the tumour should be measured to 
the nearest millimeter. 
• 	 Adequacy of excision should be assessed by the naked eye and confirmed by 
microscopic examination. Potential margins (Fig 2.2) include the pancreatic 
transection margin (with main pancreatic duct), retroperitoneal margin (defined 
as the peri-pancreatic fat tissue behind the head of the pancreas), the anterior 
pancreatic capsule and the bile duct (common bile duct or common hepatic 
duct). 
• 	 The following samples should be taken: 
proximal duodenalj gastric margin 
distal duodenal margin 
pancreas: three sections, one of which includes a complete 'en face' section 
through the distal pancreatic margin (representing the distal margin of the main 
pancreatic duct) 
common bile duct: two cross sections, one from surgical margin 
tumour: at least three sections 
uninvolved duodenum 
lymph nodes: peripancreatic (superior and inferior), pancreaticoduodenal 
(anterior and posterior), common bile duct and peri-cystic and other groups, if 
present Gejunal, omental) 














ile duct transection margin 
ancreatic transection margin 
Distal duodenal resection margin 
Pancreatic retroperitoneal 
margin 
Fig 2.2. Important resection margins in a pancreaticoduodenectomy specimen. [Adapted from 
Royal College of Pathologists' m.inimum dataset for the histopathological reporting of pancreatic, 
Ampulla of Vater and bile duct carcinoma (118).] 
2.2.2 DATA COLLECTION 
With permission from Professors Bornman and Krige of the Deparbnent of 
Hepatobiliary Surgery at Groote Schuur hospital, access to the clinical data base of the 
37 patients was obtained. Data obtained included patient demographics (age and sex), 
surgical data (date of operation and type of operation) and patient follow up (survival). 
Tumour characteristics were obtained as follows: the tumour size was recorded from the 
original pathology report. The degree of differentiation, perineural invasion, lymphatic 
invasion, vascular invasion and histological type was assessed by microscopic 
examination of the original haematoxylin and eosin (H&E) sections. If a carcinoma 
displayed more than one histological pattern, the carcinoma was classified according to 












the involvement of resection margins were obtained through a combination of 
microscopic evaluation and review of original histology reports. 
2.2.3 STATISTICAL ANYL YSIS 
Survival estimates were generated using the Kaplan-Meier survival analysis. Statistical 
significance was determinate if the two-sided P-value of a test was <0.05. Limitations of 
this study were the limited patient follow up and the limited sample size which is 
mainly due to two factors: the rarity of ampullary carcinomas as well as failure of earlier 
macroscopic reports to reveal the exact origin of the tumour. A limited sample size 
made performing quantitative analysis less than accurate. Therefore, qualitative 
analyses of the prognostic variables were performed. Selection of prognostic variables 
was based on a literature review at the time the study was commenced. Survival was 
calculated from the date of the operation to the date of last follow up (June 2003). If the 
patient died, survival was calculated from the date of the operation to the date of death. 
The potential prognostic variables included: 
immunohistochemical stains; p53, Ki-67, MUC1, MUCl core antigen, MUC2 and 
CA19,9. 
involvement of resection margins 
histological sub-type according to the criteria published by Albores-Saavedra et 
aL (73) 
TNM classification and staging according to criteria published by Flemming et 
al. (79) 
Martin's classification (59) 






















Dilution Incubation time Source 
Ki-67 Clone MIB-1 1:100 30 min OakoCytomation 
Ca19.9 (Sialyl Lewis) C241: 5:1:4 1:100 30min Novacastra 
p53 protein 00-7 1:50 30 min OakoCytomation 
MUC1 glycoprotein Ma552 1:100 30 min Novacastra 
MUC1 core glycoprotein Ma695 1:100 30 min Novacastra 
MUC2 glycoprotein Ccp58 1:100 30 min Novacastra 
Pressure cooking was used for antigen retrieval. The retrieval teclmique was as follows: 
Sections were cut 2 micrometer thick, mounted on slides coated with APES and 
incubated overnight at 60 degrees Celsius. The sections were de-waxed in xylol, 
rehydrated in graded alcohols and washed in water. Endogenous peroxidase activity 
was blocked using 2% hydrogen peroxide in water for 10 minutes. Antigen retrieval was 
performed by bringing to the boil 1.51 of O.OlM sodium sitrate buffer (pH 6.0) in a 
pressure cooker. Once the buffer had boiled, slides were placed in metal racks and 
placed in the buffer, ensuring slides were completely covered. The lid was then locked. 
Once the cooker had reached full pressure, the sections were boiled for a further two 
minutes. The cooker was removed from the heat source and immersed in cold water. 
Sections were then washed in PBS (pH 7.6). Non-specific staining was blocked by 
incubating sections in normal goat serum (DakoCytomation X0907) for 10 minutes at 
room temperature. The sections were drained and incubated with the primary 
antibodies at optimal dilution for the recommended incubation times at room 
temperature. Sections were then washed well in PBS. Sections were then treated with a 
horseradish peroxidase labeled polymer Envision [Dakocytomation K40001 
(monoclonal) or K4002 (polyclonal) for 30 min at room temperature. Sections were then 












(Oakocytomation K3466) for 5-10 minutes at room temperature. Sections were washed in 
water and then counterstained in aqueous haematoxylin solution, followed by 
dehydrating using graded alcohols, cleared in xylol and mounted in Entellan. 
2.2.6 IMMUNOHISTOCHEMICAL SCORING SYSTEM 
The staining of p53, CA19.9, MUC1, MUC1c and MUC2 was recorded and scored 
semiquantitavely based on the scoring system of Zhou et al. (76). The percentage of 
tumour cells which stained was scored as follows: 
o=no staining reaction 

1 = <10 % positive-stained tumour cells 

2 = 10-50% positive-stained tumour cells 

3 = >50-80% positive-stained tumour cells 

4 = >80% positive-stained tumour cells 

Final analysis was performed by using a simplified scoring system: scores 0 and 1 were 
regarded as negative, and scores 2 - 4 as positive. 
The Ki-67 labeling index was calculated based on the scoring system used by Oorandeu 
et al. (59): the mean of 10 fields with a 400x magnification was expressed as a percentage 
of labeled cells. For analysis, a score of more than 15% was recorded as being positive. 
2.3 RESULTS 
2.3.1 DESCRIPTIVE ANALYSIS 
There was a total of 37 patients - 18 (49%) of who were male and 19 (51 %) female. 
Calculated from the time of operation, the age range was from 27 to 83 years, with a 
mean age of 58.8 years and a median age of 59 years (SO 16.02). Nine patients (24%) 
underwent a standard Whipple procedure and 28 (76%) patients underwent a PPPD. 
Macroscopically, the tumour size ranged from 0.7 to 6 em with a mean of 2.5 em and a 












Fig 2.3. An ampullary tumour bulging into the duodenal lumen. A stent extending 
into the ampulla of Vater temporarily relieved the obstruction caused by the 
tumour. 
In 13 (35%) patients, residual adenoma was detected in the specimen. Five (14%) 
tumours were well differentiated, 24 (65%) tumours were moderately differentiated and 
8 (22%) tumours were poorly differentiated. No tumours were regarded as being 
undifferentiated. With histological typing, 19 (51 %) tumours were classified as intestinal 
type carcinomas (Fig 2.4), 16 (43%) as pancreaticobiliary type carcinomas (Fig 2.5) and 
the 2 (6%) tumours classified as "other type" were both mucinous (colloid) carcinomas 
(Fig 2.6). In both cases of mucinous carcinoma, more than 80% of the tumour displayed a 












Fig 2.4. Intestinal type carcinoma. 
Fig 2.5. Pancreaticobiliary type carcinoma 












Carcinoma involved the pancreatic resection margin in 2 cases (5%). Ten patients (27%) 
were lost to follow up. Follow up ranged from 2 days to 216 months with a mean follow 
up time of 65 months and a median follow up time of 38 months (SD 66.1). The patient 
who was followed up for 216 months was still alive 18 years after the operation. 
Perineural invasion (Fig. 2.7) was noted in 9 patients (24%). Vascular invasion (Fig. 2.8) 
was noted in 8 cases (22%) and lymphatic invasion was noted in 12 cases (32%). 
Fig 2.7. Perineural invasion. 












The association between NF-l and periampullary somatostatinornas is well described 
(40). The current series included a patient with ampullary adenocarcinoma as well as a 
second periampullary neuroendocrine tumour, which was proven to be a 
somatostatinoma with immunohistochemical staining. Although not indicated in the 
original clinical information, the patient was later confirmed to have NF-l after this was 
suggested by the reporting pathologist. The tumour had a distinctive packeted 
appearance with some glandular fea tures. The cytoplasm was eosinophilic, granular and 
voluminous. No psammoma bodies were noted. There was no connection with the 
ampullary adenocarcinoma (Fig 2.9). 
Fig 2.9. A & B) The somatostatinoma is composed of islands, glandular structures and trabeculae 
and can be seen to infiltrate muscle. C) The cells have voluminous eosinophilic cytoplasm and 
round nuclei with a stippled appearance. D) The positive somatostatin immunohistochemical 
stain. 
Another patient who had a Whipple resection for ampullary adenocarcinoma was a 53 
















fatty replacement. She was also known to have asthma and a cardiomyopathy. 
Lipomatous pseudohypertrophy of the pancreas is associated with chronic pulmonary 
disease (120). One is unable, given the pancreatic duct obstruction, to make a confident 
diagnosis in this patient but the co-existent asthma and cardiomyopathy was an 
interesting finding. Other interesting findings were carcinomas with squamous 
differentiation and carcinomas with numerous tumour giant cells. 
Table 2.2. A summary of the TNM classification and staging. 
T Number Percentage 
T1 9 24% 
T2 11 30% 
T3 14 38% 
T4 3 8% 
N Number Percentage 
NO 30 77% 
N1 7 23% 






















Table 2.3. A summary of Martin's classification. 
Martin classification Number Percentage 
I 5 49% 
II 7 19% 
III 7 19% 
IV 18 49% 
Table 2.4. A summary of the positive immunohistochemical stains. 
Carcinoma (n==37) Adenoma (n==7) Normal epithelium 
(n==33) 
p53 13 (35%) 3(42%) 0(0%) 
Ki-67 29 (78%) 3 (42%) 11 (33%) 
MUCI 19 (51 %) 2 (28%) 0(0%) 
MUCIc 15(40%) 2 (28%) 0(0%) 
MUC2 8 (21 %) 5 (71 %) 33 (100%) 
Ca19.9 31 (84%) 5 (71 %) 10 (30%) 
The p53 staining was strong nuclear positivity. Thirteen (35%) carcinomas stained 
positively while the normal epithelium was negative. Ki-67 staining was strong and 
nuclear. The highest percentage of staining (78%) was seen in the carcinomas (Fig 2.10). 












MUC1 and MUC1 core antigens had a similar staining pattern - strong luminal and 
cytoplasmic staining. The extra-cellular mucin was also positive. Normal epithelium, 
including the accessory pancreatic ducts, was negative with both anti-bodies. MUC1 was 
positive in just over half of the carcinomas (51 %) and MUC1 core in 40% (Fig 2.11 and 
2.12). 
Fig 2.11. A) Strong MUCI positivity in a carcinoma. The 
overlying mucosa (blue arrow) is negative. 
Fig 2.12. This picture contrasts the strong MUCI positivity 












The goblet cells in the duodenum were positive with MUC2 in all cases (Fig 2.13). Only 
21 % of the carcinomas stained positively with MUC2, the rest were negative (Fig 2.14) . 
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Fig 2.13. The photograph demonstrates MUC2 positivity in the 
non-neoplastic mucosa. 












The staining pattern for Ca19.9 was luminal and cytoplasmic. A total of 31 (84%) 
carcinomas stained positively with this stain (Fig 2.15). Five adenomas (71%) were 
positive and in 10 (30%) cases there was weak staining of the normal epithelium. 
o 
Fig 2.15. An example of CA19.9 staining in a carcinoma which 
is luminal and weak cytoplasmic. 
• 
Fig 2.16. Ca19.9: positive staining can be seen in the carcinoma 
in the left lower corner of this picture. The normal mucosa 













2.3.3 STATISTICAL RESULTS 
The detailed Kaplan Meier survival estimates for patients after Whipple resection for 
ampullary adenocarcinoma can be seen in Appendix 9. The 1 year survival estimate was 
78% (SE 0.08). The 5 year survival rate was 44% (SE 0.1) (Fig 2.17). 
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Fig 2.17. Kaplan Meier overall survival estimate 
Using the Kaplan Meier method, patients with Tl tumours had a distinctly better 
survival compared to patients with T2, T3 and T4 tumours as a group (P = 0.0009). 
However, there was no statistical significance in the survival estimates between patients 
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Fig 2.18. Kaplan Meier survival estimate influenced by T-stage, 
The overall stage is a variable which is co-linear with T-stage but is influenced by the N­
stage (M-stage was constant since no metastases were recorded). Patients with stage I 
tumours had a significantly better survival compared to patients with stage II, III and IV 
tumours (P = 0.012). However, there was no significance in the estimates between 
patients with stage II, III and IV tumours (Fig 2.19), 
Cumulative Proportion Surviving (Kaplan-Meier) 
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The immunohistochemical stains, including p53, Ki-67, MUCl, MUC1c, MUC2 and 
CA19.9 did not show any significant influence on survival, nor did perineural invasion, 
vascular invasion, lymphatic invasion, resection margins, differentiation, or histological 
type (Table 2.5). 








Martin classification 0.2 
Perineural invasion 0.72 
Vascular invasion 0.9 
Lymphatic invasion 0.7 
Histological sub-type 0.41 














The age range in this study (27 - 83 years) is very similar to that of a large study from 
the Memorial Sloan-Kettering Cancer Center (28.3 - 87 years) (27). The mean age of 58.8 
years is also similar to previous reports (27,31). The youngest patient in the collective 
reported by Howe et al. (27) had FAP. None of the younger patients in this study had 
any known disease associations. In the present study, there was a slight female 
predominance (51 %), whereas previous studies recorded a definite male predominance 
(31,55). The mean tumour size of 2.5 cm is similar to the mean size reported in previous 
studies (27). 
Intestinal type tumours (51%) were slightly more common than the pancreaticobiliary 
subtype (46%). This finding is in keeping with the study of Howe et al. (27) who found 
that most of the ampuilary cancers (70%) in their cohort of 123 patients had intestinal 
type morphology. They suggest that ampullary tumours are biologically more similar to 
intestinal than pancreatic carcinomas. However, other collectives found the 
pancreaticobiliary subtype to predominate over the intestinal subtype (76, 77). A recent 
study (2004) by Zhou et al. found a good correlation between CK7 and CK20 expression, 
and histological sub-classification. The pancreaticobiliary type carcinomas were CK7+ 
and CK20- whilst the intestinal type carcinomas were CK20+ and CK7-. In addition, they 
found all the intestinal type carcinomas in their cohort to be positive with MUC2 (79). In 
the present study, only 8 (50%) of the intestinal type tumours stained positively with 
MUC2. This finding is difficult to explain and may be due to discrepancies in the 
histolOgical classification based on examination of the H&E sections. 
Despite the fact that adenocarcinoma of the ampulla of Vater is relatively uncommon, 
there have been numerous reports on these tumours in the literature. The number of 
patients included in these studies range from 31 - 459 patients: the largest multi­
institutional study consisted of 459 patients collected from 57 centers in Japan between 
1949 and 1974 (121). The largest single institutional series consisted of 120 patients and 












The current series consists of 37 patients who had a Whipple resection for ampullary 
adenocarcinoma at a single institution from 1979 - 2003. The histopathological and the 
immunohistochemical features, most of which have been claimed to have prognostic 
significance, were examined. 
Previous studies attempting to define important prognostic variables for patients with 
ampullary carcinomas have been limited in several ways. Most have limited numbers of 
patients, operated on over several decades. Many have not performed multivariate 
analyses to identify independent prognostic factors. Perhaps the most significant 
problem with these studies is the lack of review to confirm that tumours originate from 
the ampulla of Vater. Accidental inclusion of tumours of the pancreas, bile duct or 
duodenum could dramatically alter the results of survival analysis. This is often a 
difficult task and may be subject to some interpretation on the part of the pathologist 
(27). Monson et al. found that only 74 of 104 tumours initially thought to be ampullary 
carcinomas at the Mayo Oinic could be confirmed to have arisen from the ampulla. 
Seven were reclassified as having originated from the pancreas, 6 from the bile duct, 2 
from the duodenum, and in 15, the origin could not be determined (122). 
The current study had several limitations which made the interpretation of data 
challenging. 
• 	 Firstly, due to the rarity of this tumour a limited number of cases were available 
for evaluation. 
• 	 These cases stretched over several decades and some of the earlier reports on 
patient outcome were from a time when the Whipple procedure carried with it a 
risk of substantially higher mortality than it does today. The result is that 
relatively few of these procedures were performed in the past. During the last 
two decades, improvements in anesthetic techniques, critical care and 
institutional specialization have decreased mortality rates (23). 
• 	 The macroscopic description at the time of dissection is one of the most 
important factors in the precise localization of a periampullary tumour. 












crucial for patient selection. Before the prognostic significance of the exact 
localization of these tumours was described, many tumours in this area were 
simply described as "periampullary carcinoma" or "adenocarcinoma, not 
otherwise specified". Also, in advanced disease, identifying the exact origin of 
the tumour is sometimes just not possible. If there was any doubt as to the origin 
of the tumour, the case was excluded from this study. Consequently, more than 
15 potential cases had to be omitted. 
• 	 Very few of the original reports included a block key in order to be certain where 
the specimen was sampled. This is especially important in the sampling of 
resection margins. 
• 	 Lastly, a problem hampering prognostic studies in South Africa is clinical follow 
up of patients, especially those from rural areas and previously disadvantaged 
communities. A total of 10/37 (27%) patients were lost to clinical follow up in 
this study. 
Due to the problems encountered as mentioned above, the number of patients which 
could be confidently included in this study, was much smaller than the expected 
number when this study commenced. Optimally, a cohort of at least 50 patients is 
necessary for accurate multivariate analysis. Despite the relatively small number of 
cases, multivariate analysis was performed on the potential prognostic variables and the 
5 year survival rate of the patients with follow up data was calculated. The overall 5­
year survival rate in the present study was 44%, which is comparable to post operative 
survival in cohorts stretching over a similar time frame: Howe et al. (27) (1983 - 1995) 
reported a 5 - year survival rate of 46% and Chareton et al. (1) (1970 -1992) reported a 5 
- year survival rate of 38%. It is clear that the studies which include patient data from 
long ago have not benefited from the improvements made in patient care and improved 
surgical technique over the past two decades. There are wide variations in the 5-year 
survival rates reported in the different collectives, with the lowest survival rates coming 
from series dating back many decades. The lowest 5-year survival rate (6%) was 
reported by Nakase et al. (121). Their cohort of patients stretched from 1949 - 1974. The 












consecutive patients who had a Whipple resection for ampullary carcinoma from 1988 
through 2001. 
The only prognostic variable which significantly influenced survival with multivariate 
analysis in this study was the T-stage: Tl tumours, which are co-linear with the stage 1 
tumours, had statistically significantly better survival compared to the higher stages (T2, 
T3 and T4) (Fig 2.18). However, there was no difference in survival between the T2, T3 
and T4 tumours. Neoptolemus et aL found tumour stage· to be significant by 
multivariate analysis in their study (123). Several other studies confirmed the prognostic 
value of TNM and stage groupings (105-110). Surprisingly, multivariate analysis did not 
reveal any prognostic significance for the following variables: nodal metastases, tumour 
grade, lymphatic/vascular invasion, resection margins, tumour size, Martin's 
classification or histological sub-classification (Table 2.5). Previous studies confirm the 
significant association of nodal metastases (106, 107, 111), tumour grade (105, 106, 123), 
lymphatic/vascular invasion (105, 109), resection margins (106), Martin's classification 
and tumour size (82). Kitamura et al. (80) claimed that histological sub-typing had 
prognostic value, but neither Zhou et al. (79) nor the present study could confirm this 
finding. Previous authors claimed that the absence of perineural invasion was a major 
factor associated with prolonged survival in patients with ampullary carcinomas (57, 
105). The current study could not confirm perineural invasion to be an adverse 
prognostic factor (Table 2.5). On the contrary, perineural invasion was noted in the 
patient who was still alive at 216 months follow up. The Ki-67 labeling index was also 
>15% in this case, which was found to be a poor prognostic indicator by other authors 
(113). However, this tumour displayed several of the well accepted good prognostic 
indicators including a TINOMO, stage 1 tumour, clear resection margins and no 
lymphatic invasion. 
Several immunohistochemical markers, including certain mucin core antigens, have 
been claimed to have prognostic significance in ampullary carcinomas. Prior to 
commencement of this study, a literature review produced reports on the prognostic 












MUC1, MUC1core, MUC2 (56) and CA19.9 (115,116). These immunohistochemical stains 
were therefore included in this study. 
The insignificant prognostic value of p53 in this study (Table 2.5) is in keeping with 
earlier observations that p53 over expression is not useful as a prognostic biomarker for 
ampullary carcinomas (51, 59). Neither CA19.9 nor the Ki-67 labeling index had any 
significant prognostic value in the present study (Table 2.5). There are several reports on 
the poor prognosis of ampullary carcinomas expressing CA19.9 (115, 116) and of 
carcinomas with a Ki-67 labeling index of > 15% (113). 
A previous study concluded that MUO expression in ampullary carcinomas correlated 
with a significantly poorer survival whilst patients with tumours expressing MUC2 
showed significantly more favorable survival (56). This study did not show any 
significant prognostic value for any of these mucin core antigens (Table 2.5). However, a 
striking observation was the expression of MUC1 and MUC1c in respectively 51% and 
40% of ampullary carcinomas and in 28% of adenomatous areas adjacent to carcinoma. 
No staining was observed in the normal epithelium. These findings are in concordance 
with the findings of Kitamura et aL (54) who found a high expression rate of MUC1 in 
ampullary carcinomas but rare or no expression in the adjacent normal epithelium. 
MUC2 antibody expression was the reverse of MUO and MUC1c expression; 100% of 
the adjacent normal epithelium expressed MUC2 in the goblet cells, 71% of adenomas 
and only 28% of carcinomas expressed MUC2. These findings suggest that the 
combination of MUC1 and MUC2 antibodies could be helpful in the diagnosis of 
ampullary carcinomas in small endoscopic biopsies. If the endoscopist is convinced that 
the lesion is localized in the ampulla of Vater, a positive MUC1 stain and a negative 
MUC2 stain would support the diagnOSiS of an ampullary carcinoma or dysplastic 
epithelium in an adenoma. Conversely, a negative MUC1 stain and the presence of 













In conclusion, the results of this study do not support a role for any 
immunohistochemical stains as part of the routine work-up for ampullary carcinomas. 
Despite the small number of patients, the credibility of this study lies with the strict case 
selection in order to be certain that only patients with unequivocal ampullary 
carcinomas were included in this study. This cohort consisted of a relatively small 
number of patients mainly due to the strict selection criteria and patients lost to follow 
up. 
At present the Royal College of Pathologists (RCPath) only includes TNM and stage 
grouping, resection margins, perineural invasion, vascular invasion and maximum 
tumour diameter as prognostic variables in the pathology data sheet for ampullary 
carcinomas (118). They do not consider the use of special techniques to assess DNA 
ploidy, proliferation markers, oncogenes, nuclear morphometry or mucin core antigens 
justifiable in a minimum data set. Immunohistochemistry to detect micro metastases in 
H&E stained tumour-free nodes is also not currently recommended. The current RCPath 













CHAPTER 3: HISTOCHEMICAL MUCIN PROFILE OF AMPULLARY 
CARCINOMAS 
, 
The study entailed the examination of the histochemical mucin production by ampullary 
carcinomas. The hypothesis was that certain histochemical mucin profiles may correlate 
with the histological subtyping of ampullary carcinomas. 
3.1 AIM 
• 	 To ascertain whether the histochemical mucin profile of ampullary carcinomas 
correlates with the histological sub-classification suggested by Albores -
Sevaadra et al. (77). 
3.2 MATERIALS AND METHODS 
This research proposal was submitted to the Groote Schuur Hospital! University of 
Cape Town Ethics committee and approval was obtained. 
This was a retrospective study comparing the histochemical mucin profiles of 37 
ampullary adenocarcinomas from patients who had a Whipple resection at Groote 
Schuur Hospital. Formalin fixed wax embedded tissue was retrieved from the archives 
of Anatomical Pathology Division of Groote Schuur hospital. For each case a single 
representative block was chosen. The block contained the most representative sample of 
the carcinoma. The ampullary carcinomas were classified histologically according to the 
criteria of Albores - Saavedra et al. (77). The two histochemical stains used to elucidate 
the nature of the mucin secreted were high iron diamine (HID) and the combined alcian 
blue PAS technique for acid and neutral mucins (For technique and solutions please see 
appendix 10 and 11)(124). The mucin profile of the different histological types of 












3.2.1 BACKGROUND ON MUCINS 
The different types of mucins can be divided as follows: 
Neutral mucins: there are no subdivisions to this group. They are periodic acid 
Schiff (PAS) positive but do not stain with alcian blue. 
Acidic mucins: this group is divided into sulphated mucins, carboxylated mucins 
and sulphated sialomucins. The carboxylated mucins include the sialidase-Iabile 
sialomucins (present mainly in salivary and bronchial glands), the sialidase­
resistant sialomucins (present mainly in the gastrointestinal tract) and hyaluronic 
acid (found mainly in the umbilical cord). 
The sulphated sialomucins is a controversial group and there has been some 
debate as to whether this group constitutes a separate entity or merely occurs in 
situations in which there is a mixture of a suUomucin and a sialomucin (124). 
Sulphated mucins are clearly and specifically demonstrated by the HID stain. The 
rationale is that, by treating sections with a mixture of certain diamine salts and ferric 
chloride, a black brown cationic complex is formed that bonds to sulphate containing 
moieties. Thus, with the HID stain, sulphated mucins stains black/brown, and 
carboxylated mucins stain blue (124). 
3.2.2 HISTOCHEMICAL ANALYSIS 
The HID stain was interpreted as follows: 
• 	 Mucin staining only black/brown =sulphated mucin 
• 	 Mucin staining predominantly black/brown with significant blue staining = 
predominantly sulphated mucin 
• 	 Mucin staining equally with black/brown and blue =mixed 
• 	 Mucin staining predominantly blue with some black/brown staining = 
predominantly sialomucin 












The AB PAS stain was interpreted as follows: 
• 	 Mucin staining only aquamarine = sulphated or carboxylated mucin 
• 	 Mucin staining predominantly aquamarine and significant magenta staining = 
predominantly sulphated or carboxylated mucin 
• 	 Mucin staining equally with aquamarine and magenta = mixed 
• 	 Mucin staining predominantly with magenta and significant aquamarine 
staining = predominantly neutral mucin 
• 	 Mucin staining only magenta = neutral mucin 
3.3 RESULTS 
T:tble 3.1. A summary of the mucin secreted in the different histological types of ampullary 
carcinoma. 
Su PSu Mi PSialo Sialo NS Total 
Inttype 1 5 5 3 3 2 19 
PBtype 0 6 3 4 3 0 16 
Muci 0 0 1 1 0 0 2 
All grps 1 11 10 7 6 2 37 
Abbreviations used in table 3.1: 
Su = Sulphated mucin 
PSu = Predominantly sulphated mucin 
Mi = Mixed 
PSialo = Predominantly sialomucin 
Sialo = Sialomucin 
Int type ca = Intestinal type ampullary carcinoma 
PB type = Panreaticobiliary type ampullary carcinoma 












Fig 3.1. I-ITD stain demonstrating predominantly sulphated mucins 
(black staining) and a trace of sialomucins (blue staining) in a carcinoma. 












Fig 3.3. HID stain demonstrating sialomucin in the goblet cells of the normal 
overlying epithelium. 
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• 38% of the pancreaticobiliary-type ampullary carcinomas secreted 
J . 
predominantly sulphated. mucin, 44% secreted predominantly sialomucin and 19 
I 
secreted mixed sulphated! and sialomucin. ' 
• 'One of the mucinous cJCinomas secreted predominantly carboxylated mucin ~ 
whilst the other secreted. Led sulphated and sialomucin 
In comparison with the intestinal type and the mucinous tumours, a slightly higher 
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neg neg neg neg pas neg neg 
neg pas neg neg pas neg pas 
neg pas < neg neg pas neg neg 
neg pas neg neg pas neg pas 
neg neg neg neg pas neg neg 
neg pas neg neg pas neg neg 













T N M S Martin 
3 0 0 2 4 
4 0 0 4 4 
3 0 0 2 4 
1 0 0 1 2 
1 0 0 1 2 
3 0 0 2 4 
1 0 0 1 1 
4 0 0 4 4 
2 0 0 2 2 
3 1 0 3 4 
3 0 0 2 3 
3 0 0 2 4 
1 0 0 1 1 
1 0 0 1 1 
2 1 0 3 4 
1 0 0 1 1 
3 0 0 2 4 
3 1 0 3 4 
3 0 0 2 4 
2 0 0 2 2 
3 0 0 2 4 
1 0 0 1 1 
2 0 0 2 2 
2 0 0 2 3 
2 0 0 2 3 
2 0 0 2 3 
2 0 0 2 3 
3 1 0 2 4 
2 0 0 2 3 
3 1 0 3 4 
2 1 0 3 4 
1 0 0 1 2 
3 1 0 3 4 
3 0 0 2 4 
4 0 0 3 4 
2 0 0 2 3 













date of survival 7/2003 or 
status death dod folllow update of op 
5/9/1979 died 2215/1996 192 m 286m 
22/12/1980 died 23/311984 39m 271m 
14/1/1981 died 31211981 1m 270m 
21101/1981 died 1984 36m 270m 
13/711981 lost lost lost 
20/10/1983 died 22/10/1983 2d 237m 
28/06/1985 alive 216m 216m 
14/10/1985 died 26/05/1992 79m 213m 
22/07/1987 lost lost lost 
25/05/1987 lost lost lost 
23/12/1987 lost lost lost 
26/11/1987 died unknown unknown 188m 
30/11/1987 alive 188m 188m 
25/511989 alive 169m 169m 
21411991 lost lost lost 
1912/1992 alive 137m 137m 
29/4/1992 lost lost lost 
12/6/1992 died 1995 133m 133m 
11/9/1992 lost lost lost 
91311993 died 1/4/1997 48m 124m 
3/3/1993 died 21105/1996 38m 124m 
10/11/1993 alive 116m 116m 
17/811994 died 20/08/1997 36m 107m 
30/111995 alive 102m 102m 
11/12/1995 died 1996 5m 91m 
30/811995 lost lost lost 
171711996 died 1997 8m 84m 
15/5/1997 died 1998 10m 74m 
1/911999 died 51812001 23m 46m 
29/9/1999 lost lost lost 
29/9/1999 died 12/5/2003 43m 45m 
3/12/2001 alive 21m 21m 
4/112001 alive 31m 31m 
21/7/2001 died 21107/2002 12m 24m 
20/2/2002 alive 17m 17m 
18/3/2002 alive 16m 16m 














LSUIRVIVAl ! SE 
0.0600 0.962963 0.036345 
1.0000 0.925926 0.050401 
5.0000 0.888889 0.060481 
8.0000 0.851852 0.068367 
10.0000 0.814815 0.074757 




23.0000 0.734568 0.086448 
31.0000 
36.0000 0.688657 0.092436 
36.0000 0.642747 0.097007 
38.0000 0.596836 0.100356 
39.0000 0.550926 0.102602 
43.0000 0.505015 0.103816 
47.0000 
48.0000 0.454514 0.105002 
79.0000 0.404012 0.104778 
102.0000 
116.0000 


















Combined aldan blue-PAS technique for acid and neutral mudns (Mowry 1956) 
Preperation of stains 
a) Alcian blue: 
Alcian blue Ig 
3 percent acetic acid 100mI 
b) Schiff's reagent 
Basic fuchsin Ig 
Distilled water 200mI 
Potasium or sodium metabisulphate 2g 
Analar cone. Hydrochloric acid 2mI 
Decolourizing charcoal 2g 
Method 
1. Dewax sections and bring to water. 
2. Aldan blue solution, 5min. 
3. Wash in water, then distilled water. 
4. 1 per cent aqueous periodic acid,S min. 
5. Rinse well in distilled water. 
6. Schiff's reagent, 15 min. 
7. Wash in running tap water, 5-10 minutes. 
8. Stain nuclei lightly with one of the usual haematoxylin solutions; differentiate as 
appropriate and blue. 
9. Wash in water. 
10. Rinse in absolute alcohol. 













High iron diamine (Spicer 1965) 
Solutions 
1. High iron diamine: 
N, N-dimethyl-meta-phenylenediamine dihydrochloride 120mg 
N, N-dimethyl-para-phenylenediamine dihydrochloride 20mg 
Distilled water 50ml 
Ferric chloride (60% BDH solution) 1.4ml 
Dissolve the two diamine salts simultaneously in the distilled water and then add the 
ferric chloride solution and mix. 
2. 1% alcian blue in 3%acetic acid 
3.0.5% aqueous neutral red 
Technique 
1. Positive control and the test sections to distilled water. 
2. Treat all sections with the high iron diamine solution for 18-24 h. 
3. Wash well in running water. 
4. Stain with aldan blue solution for 5 minutes. 
5. Wash in water, stain nuclei with the neutral red solution for 2-3 minutes 













NATIONAL MINIMUM DATASET 
AMPULl.ARY CARCINOMA HISTOPATHOLOGY REPORT 
Hospital .••. _ .•• _._._......••.••__.. Hospi",1 no .____............ NHS no •._ .....•.••••••..••......••. 

Oate of request ...•••••• _ ••. _._••.•••.. Date of reponing•••••••••••_._...__ Report 00....................... 

Patn,ilogjst •..•.•..•.....•....••_......._.••...._ Surgeon ...•••••..••.•...••......••••••••• _ ...................... 

Type of spc:cimen; ................................................................................................... . 

S~d~ 
l.engtb of doodentml ••••..... rnm 
f..ength of lesser curve ••••..... mm 
U:ngdl of greater c:u1'Ve......... mm 
l.engd> of gall hladder ..•.••_. mm 
Length of bile duel: •.•...•.• mm 
Size of P'"nc:te2S •.••••••• >: ••••••••• x ••••••••• mm 
TypcoftumOtnr Adenocarxinoma 
Well 
Mru:imum dqIch ofjn~ rn 
Tis: Can:iooma in situ 
Tt, T"rn<:>trr fimired to ampulla of Valet' 
or spbino::teT of OM 
Th Tumour inw.des the duodenal wall 
T3, Tumour invades 20 mm or Icss 
inro pancreas 
T4: 	 Tumour invades more dr.tn 20 mm 







Iles«:tion margin involw:menr Yes 

.l.ympb node involvement (N) 

Total oumher of noo"" 

N umber of nocie.s involved 

NX, Cann""be~ 
No, R~ lymph nodes· not in""l=I 
NI, Regi«!allymp" <IO<b'" inn>l_"",, 
• p~..". ..xt_Figu"" l{arbficitfunof~~ 
Maximum rumour dia:mett:r ••..•••..•. rum 
Other organs .••.•••••....••.••••....•.....••••... 
Named _I idettrified Yes No 
Which vessel? ••....•.••••••.••......••.••..••...•. 
Scent in plaa: Yes No 
Othec (see Table 3) ......••••••••••..••..••••...•... 
Poor 
Perineural invasion Yes 
NOImed vessel in"olnd Yes No 
If y<:s, which margin •..•.••.....•.••••••• 






S;gnaruc." ..•.•••••..•.•••......•..••.•.••••• _ Da«:: •••.••••......••.• _ •.... SNOMed codes:••..•....•.•••••..•• 
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